Key statistics
On Friday, Ocugen Inc (2H51:HAM) closed at 0.9905, 204.39% above the 52 week low of 0.3254 set on Dec 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.00 |
---|---|
High | 1.00 |
Low | 0.9905 |
Bid | 0.991 |
Offer | 1.03 |
Previous close | 1.03 |
Average volume | 112.00 |
---|---|
Shares outstanding | 287.86m |
Free float | 283.79m |
P/E (TTM) | -- |
Market cap | 319.52m USD |
EPS (TTM) | -0.1785 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 16:25 BST.
More ▼
Announcements
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
- Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
- Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
- Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
- Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
- Ocugen Provides Business Update with Second Quarter 2024 Financial Results
- Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
- Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
- Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
- Ocugen, Inc. Announces Proposed Public Offering of Common Stock
More ▼